| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
School of Molecular and Biomedical Science, University of Adelaide (A.D., K.A.M., J.C.W., B.E.F.), Adelaide 5005, Australia; Departments of Pediatrics (M.J.E.W., H.v.D., J.M.W., M.K.) and Endocrinology and Metabolic Diseases (M.K.), Leiden University Medical Center, 2300RC Leiden, The Netherlands; and Walter and Eliza Hall Institute of Medical Research (C.C.W., R.S.N.), Victoria 3050, Australia
Address all correspondence and requests for reprints to: Dr. Briony E. Forbes, University of Adelaide, Adelaide, 5005 South Australia, Australia. E-mail: briony.forbes{at}adelaide.edu.au.
We have previously described the phenotype resulting from a missense mutation in the IGF-I gene, which leads to expression of IGF-I with a methionine instead of a valine at position 44 (Val44Met IGF-I). This mutation caused severe growth and mental retardation as well as deafness evident at birth and growth retardation in childhood, but is relatively well tolerated in adulthood. We have conducted a biochemical and structural analysis of Val44Met IGF-I to provide a molecular basis for the phenotype observed. Val44Met IGF-I exhibits a 90-fold decrease in type 1 IGF receptor (IGF-1R) binding compared with wild-type human IGF-I and only poorly stimulates autophosphorylation of the IGF-1R. The ability of Val44Met IGF-I to signal via the extracellular signal-regulated kinase 1/2 and Akt/protein kinase B pathways and to stimulate DNA synthesis is correspondingly poorer. Binding or activation of both insulin receptor isoforms is not detectable even at micromolar concentrations. However, Val44Met IGF-I binds IGF-binding protein-2 (IGFBP-2), IGFBP-3, and IGFBP-6 with equal affinity to IGF-I, suggesting the maintenance of overall structure, particularly in the IGFBP binding domain. Structural analysis by nuclear magnetic resonance confirms retention of near-native structure with only local side-chain disruptions despite the significant loss of function. To our knowledge, our results provide the first structural study of a naturally occurring mutant human IGF-I associated with growth and developmental abnormalities and identifies Val44 as an essential residue involved in the IGF-IGF-1R interaction.
This article has been cited by other articles:
![]() |
L. Laviola, A. Natalicchio, S. Perrini, and F. Giorgino Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E991 - E999. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gauguin, C. Delaine, C. L. Alvino, K. A. McNeil, J. C. Wallace, B. E. Forbes, and P. De Meyts Alanine Scanning of a Putative Receptor Binding Surface of Insulin-like Growth Factor-I J. Biol. Chem., July 25, 2008; 283(30): 20821 - 20829. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Surinya, B. E. Forbes, F. Occhiodoro, G. W. Booker, G. L. Francis, K. Siddle, J. C. Wallace, and L. J. Cosgrove An Investigation of the Ligand Binding Properties and Negative Cooperativity of Soluble Insulin-like Growth Factor Receptors J. Biol. Chem., February 29, 2008; 283(9): 5355 - 5363. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gauguin, B. Klaproth, W. Sajid, A. S. Andersen, K. A. McNeil, B. E. Forbes, and P. De Meyts Structural Basis for the Lower Affinity of the Insulin-like Growth Factors for the Insulin Receptor J. Biol. Chem., February 1, 2008; 283(5): 2604 - 2613. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Delaine, C. L. Alvino, K. A. McNeil, T. D. Mulhern, L. Gauguin, P. De Meyts, E. Y. Jones, J. Brown, J. C. Wallace, and B. E. Forbes A Novel Binding Site for the Human Insulin-like Growth Factor-II (IGF-II)/Mannose 6-Phosphate Receptor on IGF-II J. Biol. Chem., June 29, 2007; 282(26): 18886 - 18894. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vidarsdottir, M. J. E. Walenkamp, A. M. Pereira, M. Karperien, J. van Doorn, H. A. van Duyvenvoorde, S. White, M. H. Breuning, F. Roelfsema, M. F. Kruithof, et al. Clinical and Biochemical Characteristics of a Male Patient with a Novel Homozygous STAT5b Mutation J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3482 - 3485. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. E. Walenkamp, H. J. van der Kamp, A. M. Pereira, S. G. Kant, H. A. van Duyvenvoorde, M. F. Kruithof, M. H. Breuning, J. A. Romijn, M. Karperien, and J. M. Wit A Variable Degree of Intrauterine and Postnatal Growth Retardation in a Family with a Missense Mutation in the Insulin-Like Growth Factor I Receptor J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3062 - 3070. [Abstract] [Full Text] [PDF] |
||||
![]() |
V.C. Epa and C. W. Ward Model for the complex between the insulin-like growth factor I and its receptor: towards designing antagonists for the IGF-1 receptor Protein Eng. Des. Sel., August 1, 2006; 19(8): 377 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Schlueter, T. Royer, M. H. Farah, B. Laser, S. J. Chan, D. F. Steiner, and C. Duan Gene duplication and functional divergence of the zebrafish insulin-like growth factor 1 receptors FASEB J, June 1, 2006; 20(8): 1230 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. E. Walenkamp, M. Karperien, A. M. Pereira, Y. Hilhorst-Hofstee, J. van Doorn, J. W. Chen, S. Mohan, A. Denley, B. Forbes, H. A. van Duyvenvoorde, et al. Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2855 - 2864. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |